The stock price of Ocular Therapeutix Inc (NASDAQ: OCUL) has surged by 0.11 when compared to previous closing price of 8.90, but the company has seen a 6.96% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-14 that BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May 2025.
Is It Worth Investing in Ocular Therapeutix Inc (NASDAQ: OCUL) Right Now?
OCUL has 36-month beta value of 1.41. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 6 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for OCUL is 133.72M, and currently, short sellers hold a 10.34% ratio of that float. The average trading volume of OCUL on June 11, 2025 was 1.77M shares.
OCUL’s Market Performance
OCUL’s stock has seen a 6.96% increase for the week, with a 26.20% rise in the past month and a 4.70% gain in the past quarter. The volatility ratio for the week is 3.39%, and the volatility levels for the past 30 days are at 4.08% for Ocular Therapeutix Inc The simple moving average for the last 20 days is 13.99% for OCUL stock, with a simple moving average of 5.32% for the last 200 days.
Analysts’ Opinion of OCUL
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see OCUL reach a price target of $17. The rating they have provided for OCUL stocks is “Outperform” according to the report published on March 18th, 2025.
Needham gave a rating of “Buy” to OCUL, setting the target price at $15 in the report published on March 11th of the current year.
OCUL Trading at 17.87% from the 50-Day Moving Average
After a stumble in the market that brought OCUL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.33% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCUL starting from Waheed Nadia, who sale 13,861 shares at the price of $8.05 back on Jun 02 ’25. After this action, Waheed Nadia now owns 206,805 shares of Ocular Therapeutix Inc, valued at $111,581 using the latest closing price.
NADIA K. WAHEED, the Officer of Ocular Therapeutix Inc, proposed sale 13,861 shares at $8.05 during a trade that took place back on Jun 02 ’25, which means that NADIA K. WAHEED is holding shares at $111,524 based on the most recent closing price.
Stock Fundamentals for OCUL
Current profitability levels for the company are sitting at:
- -3.43 for the present operating margin
- 0.91 for the gross margin
The net margin for Ocular Therapeutix Inc stands at -3.23. The total capital return value is set at -0.55. Equity return is now at value -57.19, with -40.79 for asset returns.
Based on Ocular Therapeutix Inc (OCUL), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -1.91. The debt to equity ratio resting at 0.29. The interest coverage ratio of the stock is -31.2.
Currently, EBITDA for the company is -176.14 million with net debt to EBITDA at 1.52. When we switch over and look at the enterprise to sales, we see a ratio of 19.23. The receivables turnover for the company is 2.36for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.22.
Conclusion
To put it simply, Ocular Therapeutix Inc (OCUL) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
